ABBV vs. HLN: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ABBV and HLN, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
ABBV dominates in value with a market cap of 321.13 billion USD, eclipsing HLN’s 50.06 billion USD by roughly 6.41×.
ABBV’s beta of 0.55 points to much larger expected swings compared to HLN’s calmer 0.20, suggesting both higher upside and downside potential.
HLN is an ADR, letting U.S. buyers tap its non-U.S. business directly, unlike ABBV, which is purely domestic.
| Symbol | ABBV | HLN |
|---|---|---|
| Company Name | AbbVie Inc. | Haleon plc |
| Country | US | GB |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - Specialty & Generic |
| CEO | Mr. Robert A. Michael CPA | Mr. Brian James McNamara |
| Price | 181.8 USD | 11.1 USD |
| Market Cap | 321.13 billion USD | 50.06 billion USD |
| Beta | 0.55 | 0.20 |
| Exchange | NYSE | NYSE |
| IPO Date | January 2, 2013 | July 25, 2022 |
| ADR | No | Yes |
Performance Comparison
This chart compares the performance of ABBV and HLN over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of ABBV and HLN based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- HLN shows a negative forward PEG of -0.26, signaling expected earnings contraction, while ABBV at 7.16 maintains analysts’ projections for stable or improved profits.
| Symbol | ABBV | HLN |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 76.62 | 26.08 |
| Forward PEG Ratio (TTM) | 7.16 | -0.26 |
| Price-to-Sales Ratio (P/S, TTM) | 5.60 | 3.31 |
| Price-to-Book Ratio (P/B, TTM) | 226.35 | 2.33 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 20.87 | 0.00 |
| EV-to-EBITDA (TTM) | 23.58 | 19.43 |
| EV-to-Sales (TTM) | 6.73 | 4.01 |
| EV-to-Free Cash Flow (TTM) | 25.08 | 0.00 |
Dividend Comparison
ABBV’s dividend yield of 3.51% is about 119% higher than HLN’s 1.60%, underscoring its stronger focus on returning cash to shareholders.
| Symbol | ABBV | HLN |
|---|---|---|
| Dividend Yield (TTM) | 3.51% | 1.60% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of ABBV and HLN, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- With current ratios of 0.76 and 0.98, both ABBV and HLN have less current assets than short-term liabilities, which could strain their working capital and force reliance on additional financing.
- Both ABBV (quick ratio 0.64) and HLN (quick ratio 0.78) fall below 0.8, meaning their most liquid assets—excluding inventory—aren’t enough to meet short-term obligations. This could force them to rely on receivables, inventory turn, or external financing.
- ABBV is heavily leveraged (debt-to-equity ratio 49.22), which can boost returns but raises risk if borrowing costs climb, while HLN at 0.62 keeps leverage at a more moderate level.
| Symbol | ABBV | HLN |
|---|---|---|
| Current Ratio (TTM) | 0.76 | 0.98 |
| Quick Ratio (TTM) | 0.64 | 0.78 |
| Debt-to-Equity Ratio (TTM) | 49.22 | 0.62 |
| Debt-to-Assets Ratio (TTM) | 0.51 | 0.29 |
| Interest Coverage Ratio (TTM) | 6.14 | 5.60 |